Want to see FR:ALTHX full AI Analyst Report?
ALTHX Stock Chart & Stats
€2.03
-€0.01(-2.06%)
At close: 4:00 PM EST
€2.03
-€0.01(-2.06%)
Day’s Range― - ―
52-Week Range€0.94 - €5.10
Previous CloseN/A
Volume1.58K
Average Volume (3M)133.77K
Market Cap
€47.79M
Enterprise Value€37.19M
Total Cash (Recent Filing)€7.77M
Total Debt (Recent Filing)€2.88M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding14,472,778
10 Day Avg. Volume147,352
30 Day Avg. Volume133,766
Financial Highlights & Ratios
PEG Ratio-2.04
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CNS / Rare-disease Focus With Partner-driven ModelA focused CNS and rare-disease strategy concentrates R&D on high unmet-need niches where clinical wins can command premium positioning. Coupling clinical-stage programs with partnerships helps spread development risk and conserve internal resources, a durable advantage for a small biotech.
Improving Cash-burn Trend In 2024–2025An observable reduction in cash burn over multiple years suggests better cost discipline or program prioritization, which extends runway and reduces near-term financing pressure. If sustained, improved FCF trends materially lower execution risk versus prior years.
Lean Operating Structure (small Headcount)A very small employee base implies a lean cost structure and reliance on external partners/contractors, allowing capital to be focused on core clinical programs. This operating model can preserve cash and enable flexibility across development stages over the medium term.
Bears Say
Chronic Negative Cash GenerationPersistent negative operating and free cash flow forces repeated external financing or asset sales. Over months this erodes strategic optionality, risks dilutive capital raises, and constrains the ability to fund multi-year clinical programs without partner or investor support.
Revenue Collapse And Weak Revenue VisibilityA complete drop to zero revenue in a reported year signals fragile commercial traction or one-off revenue loss, sharply increasing funding dependence. Sustained absence of revenue undermines internal funding capacity and raises execution risk for advancing clinical projects.
Balance-sheet Fragility And Meaningful LeverageMaterial leverage versus a small asset base and prior negative equity indicate limited financial buffers. This fragility makes the company susceptible to adverse trial or funding outcomes and likely necessitates dilutive financing or non-dilutive partnerships to sustain operations.
Theranexus SA News
ALTHX FAQ
What was Theranexus SA’s price range in the past 12 months?
Theranexus SA lowest stock price was €0.94 and its highest was €5.10 in the past 12 months.
What is Theranexus SA’s market cap?
Theranexus SA’s market cap is €47.79M.
When is Theranexus SA’s upcoming earnings report date?
Theranexus SA’s upcoming earnings report date is Sep 24, 2026 which is in 83 days.
How were Theranexus SA’s earnings last quarter?
Currently, no data Available
Is Theranexus SA overvalued?
According to Wall Street analysts Theranexus SA’s price is currently Overvalued.
Does Theranexus SA pay dividends?
Theranexus SA does not currently pay dividends.
What is Theranexus SA’s EPS estimate?
Theranexus SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theranexus SA have?
Theranexus SA has 14,472,778 shares outstanding.
What happened to Theranexus SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theranexus SA?
Currently, no hedge funds are holding shares in FR:ALTHX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theranexus SA
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
Technical Analysis
GenSight Biologics SA
―
AB Science SA
―
Sensorion SAS
―
Intrasense SA
―
MedinCell SA
―
Options Prices
Currently, No data available
---